Physician profile
Ann E Patterson
NPI 1053544585
$2,734.60
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $850 · 2022: $737 · 2023: $732 · 2024: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $552.75 | 2021-2024 | |
| Amgen INC. | $351.76 | 2021-2024 | Repatha, Prolia, Evenity |
| Novo Nordisk INC | $196.54 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $186.45 | 2022-2024 | Veozah |
| Abbvie INC. | $170.70 | 2021-2024 | |
| Lilly USA, LLC | $166.26 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $140.69 | 2021-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.91 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| Mylan Specialty L.P. | $125.07 | 2021-2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $77.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $75.52 | 2021-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $75.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.44 | 2021-2022 | |
| Sanofi Pasteur INC. | $54.41 | 2021-2023 | |
| Esperion Therapeutics, INC. | $46.27 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.68 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $34.89 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $33.36 | 2023 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $31.32 | 2024 | |
| Amarin Pharma, INC. | $28.12 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.97 | 2021 | |
| Glaxosmithkline, LLC. | $27.32 | 2024 | Bexsero, Pediarix, Rotarix |
| Eisai INC. | $25.70 | 2021 | |
| Biogen, INC. | $23.59 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.89 | 2021 | |
| Harmony Biosciences LLC | $15.64 | 2022 | |
| Exact Sciences Corporation | $15.22 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.